-
公开(公告)号：US20190224190A1
公开(公告)日：2019-07-25
申请号：US16374430
申请日：2019-04-03
Applicant: Takeda Pharmaceutical Company Limited
Inventor： John David Lawson , Mark Sabat , Nicholas Scorah , Christopher Smith , Phong H. Vu , Haixia Wang
IPC: A61K31/4725 , C07D401/04 , C07D403/14 , A61P35/02 , A61K31/4375 , C07D401/14 , A61K31/519 , A61K31/4439 , C07D471/04
Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
-
公开(公告)号：US10328089B2
公开(公告)日：2019-06-25
申请号：US15796519
申请日：2017-10-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Zacharia Cheruvallath , John David Lawson , Christopher McBride
IPC: A61K31/665 , A61K31/683 , A61K45/06 , C07F9/6558 , A61K31/66 , A61K38/28 , A61K31/155 , A61K31/192 , A61K31/216 , A61K31/336 , A61K31/397 , A61K31/4985 , A61K31/662 , A61P3/10 , A61K31/64
Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof and pharmaceutically acceptable salts of the compounds and stereoisomers, wherein R1 and R2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
-
公开(公告)号：US09402841B2
公开(公告)日：2016-08-02
申请号：US14203366
申请日：2014-03-10
Applicant: Takeda Pharmaceutical Company Limited
Inventor： John David Lawson , Mark Sabat , Nicholas Scorah , Christopher Smith , Phong H. Vu , Haixia Wang
IPC: A61K31/47 , C07D471/02 , C07D217/22 , C07D217/00 , C07D217/02 , A61K31/44 , C07D401/00 , A61K31/4725 , A61K31/4375 , A61K31/4439 , A61K31/519 , C07D401/14 , C07D471/04 , C07D401/04 , C07D403/14
CPC classification number: A61K31/4725 , A61K31/4375 , A61K31/4439 , A61K31/519 , A61P35/02 , C07D401/04 , C07D401/14 , C07D403/14 , C07D471/04
Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
Abstract translation: 公开了式1的化合物或其药学上可接受的盐，其中R 1，R 2，R 3和R 4在说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗I型超敏反应，自身免疫性疾病，炎症性疾病，癌症，非恶性增殖性疾病和其它病症的用途 与BTK相关。
-
公开(公告)号：US09434743B2
公开(公告)日：2016-09-06
申请号：US14378305
申请日：2013-02-28
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Zacharia Cheruvallath , Philip Erickson , Jun Feng , Mallareddy Komandla , John David Lawson , Christopher McBride , Joanne Miura , Sean Murphy , Mingnam Tang , Huong-Thu Ton-Nu
IPC: C07D498/04 , C07D401/04 , C07D471/04 , C07D403/04 , C07D405/04 , C07D417/04 , C07D487/04 , C07D401/14 , C07D413/14 , C07D231/56 , C07D403/10 , C07D407/14 , C07D413/04 , C07D413/10 , A61K31/416 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06
CPC classification number: C07D498/04 , A61K31/416 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07D231/56 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D407/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
-
公开(公告)号：US20150038510A1
公开(公告)日：2015-02-05
申请号：US14381187
申请日：2013-03-25
Applicant: Takeda Pharmaceutical Company Limited
Inventor： John David Lawson , Mark Sabat , Christopher Smith , Haixia Wang , Young K. Chen , Toufike Kanouni
IPC: C07D471/04 , A61K31/502 , C07D403/04 , C07D409/14 , C07D403/14 , C07D405/14 , C07D417/14 , A61K31/5377 , A61K45/06
CPC classification number: C07D471/04 , A61K31/502 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D403/04 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D413/14 , C07D417/14 , Y02A50/401
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification. The compounds are inhibitors of Bruton's tyrosine kinase (BTK). This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with BTK.
Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4和R 5在本说明书中定义。 这些化合物是Bruton酪氨酸激酶（BTK）的抑制剂。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗与BTK相关的疾病，病症或病症的用途。
-
Patent Agency Ranking
公开(公告)号：US20150005232A1
公开(公告)日：2015-01-01
申请号：US14378305
申请日：2013-02-28
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Zacharia Cheruvallath , Philip Erickson , Jun Feng , Mallareddy Komandla , John David Lawson , Christopher McBride , Joanne Miura , Sean Murphy , Mingnam Tang , Huong-Thu Ton-Nu
IPC: C07D498/04 , A61K31/416 , A61K45/06 , C07D401/04 , A61K31/4439 , C07D471/04 , A61K31/437 , A61K31/5383 , C07D403/04 , A61K31/506 , C07D405/04 , C07D413/10 , A61K31/4245 , C07D417/04 , A61K31/427 , C07D401/14 , A61K31/5377 , C07D487/04 , A61K31/53 , C07D231/56
CPC classification number: C07D498/04 , A61K31/416 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07D231/56 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D407/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5和R 6在本说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗与MetAP2相关的肥胖症和相关疾病，病症和病症的用途。
-
公开(公告)号：US20140256734A1
公开(公告)日：2014-09-11
申请号：US14203366
申请日：2014-03-10
Applicant: Takeda Pharmaceutical Company Limited
Inventor： John David Lawson , Mark Sabat , Nicholas Scorah , Christopher Smith , Phong H. Vu , Haixia Wang
IPC: A61K31/4725 , A61K31/4439 , C07D471/04 , A61K31/4375 , C07D401/14 , A61K31/519
CPC classification number: A61K31/4725 , A61K31/4375 , A61K31/4439 , A61K31/519 , A61P35/02 , C07D401/04 , C07D401/14 , C07D403/14 , C07D471/04
Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
Abstract translation: 公开了式1的化合物或其药学上可接受的盐，其中R 1，R 2，R 3和R 4在说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗I型超敏反应，自身免疫性疾病，炎症性疾病，癌症，非恶性增殖性疾病和其它病症的用途 与BTK相关。
-
公开(公告)号：US10307414B2
公开(公告)日：2019-06-04
申请号：US15717624
申请日：2017-09-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： John David Lawson , Mark Sabat , Nicholas Scorah , Christopher Smith , Phong H. Vu , Haixia Wang
IPC: A61K31/4439 , A61K31/4725 , A61P35/02 , A61K31/4375 , A61K31/519 , C07D401/14 , C07D471/04 , C07D401/04 , C07D403/14
Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
-
公开(公告)号：US09801872B2
公开(公告)日：2017-10-31
申请号：US15197051
申请日：2016-06-29
Applicant: Takeda Pharmaceutical Company Limited
Inventor： John David Lawson , Mark Sabat , Nicholas Scorah , Christopher Smith , Phong H. Vu , Haixia Wang
IPC: A61K31/44 , A61K31/4725 , A61K31/4375 , A61K31/4439 , A61K31/519 , C07D401/14 , C07D471/04 , C07D401/04 , C07D403/14
CPC classification number: A61K31/4725 , A61K31/4375 , A61K31/4439 , A61K31/519 , A61P35/02 , C07D401/04 , C07D401/14 , C07D403/14 , C07D471/04
Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
-
公开(公告)号：US20160175332A1
公开(公告)日：2016-06-23
申请号：US14974033
申请日：2015-12-18
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Zacharia Cheruvallath , John David Lawson , Christopher McBride
IPC: A61K31/665 , C07F9/6558 , A61K31/683 , A61K45/06
CPC classification number: A61K31/665 , A61K31/155 , A61K31/192 , A61K31/216 , A61K31/336 , A61K31/397 , A61K31/4985 , A61K31/64 , A61K31/66 , A61K31/662 , A61K31/683 , A61K38/28 , A61K45/06 , A61P3/10 , C07F9/65586 , A61K2300/00
Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof and pharmaceutically acceptable salts of the compounds and stereoisomers, wherein R1 and R2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
Abstract translation: 公开了式1的化合物，其立体异构体和化合物和立体异构体的药学上可接受的盐，其中R1和R2在说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗与MetAP2相关的肥胖症和相关疾病，病症和病症的用途。
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.028 seconds)
